Edition:
United Kingdom

Amphastar Pharmaceuticals Inc (AMPH.OQ)

AMPH.OQ on NASDAQ Stock Exchange Global Select Market

20.07USD
20 Nov 2018
Change (% chg)

$-0.44 (-2.15%)
Prev Close
$20.51
Open
$20.27
Day's High
$20.60
Day's Low
$20.02
Volume
63,663
Avg. Vol
71,186
52-wk High
$21.65
52-wk Low
$14.40

Latest Key Developments (Source: Significant Developments)

Amphastar Pharmaceuticals Files For Mixed Shelf Of Up To $250 Million
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION – SEC FILING.  Full Article

Amphastar Pharmaceuticals Announces Reintroduction Of Primatene Mist
Thursday, 8 Nov 2018 

Nov 7 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS, INC. ANNOUNCES REINTRODUCTION OF PRIMATENE® MIST.AMPHASTAR PHARMACEUTICALS INC- AMPHASTAR ANTICIPATES THAT PRIMATENE MIST WILL BE AVAILABLE IN MAJOR DRUG STORES ACROSS UNITED STATES IN EARLY 2019.AMPHASTAR PHARMACEUTICALS - U.S. FOOD AND DRUG ADMINISTRATION GRANTED APPROVAL OF ITS NEW DRUG APPLICATION FOR PRIMATENE MIST.  Full Article

Amphastar Pharmaceuticals Q2 GAAP Loss Per Share $0.06
Wednesday, 8 Aug 2018 

Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE THREE MONTHS ENDED JUNE 30, 2018.Q2 GAAP LOSS PER SHARE $0.06.Q2 REVENUE $71 MILLION VERSUS I/B/E/S VIEW $62.9 MILLION.Q2 ADJUSTED NON-GAAP EARNINGS PER SHARE $0.03.Q2 EARNINGS PER SHARE VIEW $0.07 -- THOMSON REUTERS I/B/E/S.  Full Article

Amphastar Announces Expansion Of Amphastar Nanjing Pharmaceuticals
Monday, 9 Jul 2018 

July 9 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR ANNOUNCES EXPANSION OF AMPHASTAR NANJING PHARMACEUTICALS INC..AMPHASTAR PHARMACEUTICALS INC - TO HELP FUND EXPANSION, UNIT COMPLETED PRIVATE PLACEMENT OF EQUITY, RAISING ABOUT $57 MILLION.AMPHASTAR - AFTER EXPANSION, UNIT INTENDS TO BEGIN SELLING APIS BOTH TO AMPHASTAR AND EXTERNALLY AROUND WORLD TO EXPAND OVERALL MARKETS.  Full Article

Amphastar Announces Approval For Isoproterenol Hydrochloride Injection
Tuesday, 19 Jun 2018 

June 19 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR ANNOUNCES APPROVAL FOR ISOPROTERENOL HYDROCHLORIDE INJECTION, USP.AMPHASTAR PHARMACEUTICALS INC - ANTICIPATES LAUNCHING PRODUCT IN Q3 OF 2018..AMPHASTAR PHARMACEUTICALS- FDA GRANTED APPROVAL OF ANDA FOR ISOPROTERENOL HYDROCHLORIDE INJECTION USP 0.2MG/ML, 1ML AND 0.2MG/ML, 5ML SINGLE DOSE VIAL.  Full Article

Amphastar Pharmaceuticals Receives FDA Approval For Calcium Chloride Injection
Monday, 14 May 2018 

May 14 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR PHARMACEUTICALS RECEIVES FDA APPROVAL FOR CALCIUM CHLORIDE INJECTION.AMPHASTAR PHARMACEUTICALS - FDA GRANTED APPROVAL OF ANDA FOR CALCIUM CHLORIDE INJECTION 10% IN 10 ML LUER-JET PREFILLED SYRINGE SYSTEM.  Full Article

Amphastar Announces Approval For Sodium Nitroprusside Injection, USP
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR ANNOUNCES APPROVAL FOR SODIUM NITROPRUSSIDE INJECTION, USP.AMPHASTAR PHARM - ANTICIPATES LAUNCHING SODIUM NITROPRUSSIDE INJECTION, USP IN Q1 OF 2018.AMPHASTAR PHARMACEUTICALS - FDA GRANTED APPROVAL OF ABBREVIATED NEW DRUG APPLICATION FOR SODIUM NITROPRUSSIDE INJECTION 25MG/ML, 2ML SINGLE DOSE VIAL.  Full Article

Amphastar Announces Approval For Medroxyprogesterone Acetate Injectable Suspension, USP
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Amphastar Pharmaceuticals Inc ::AMPHASTAR ANNOUNCES APPROVAL FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, USP.SAYS AMPHASTAR ANTICIPATES LAUNCHING ITS PRODUCT IN Q1 OF 2018.SAYS U.S. FDA GRANTED APPROVAL OF 2 ABBREVIATED NEW DRUG APPLICATIONS FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION.SAYS APPROVAL FOR MEDROXYPROGESTERONE ACETATE INJECTABLE SUSPENSION, USP 150 MG/ML, 1ML VIAL, & 1ML PREFILLED SYRINGE, RESPECTIVELY.  Full Article

Amphastar Pharma reports results for three months ended Sept
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Amphastar Pharmaceuticals Inc :Amphastar Pharmaceuticals reports financial results for the three months ended September 30, 2017.Q3 GAAP earnings per share $0.00.Q3 revenue $57.9 million versus i/b/e/s view $57.2 million.Q3 adjusted non-GAAP earnings per share $0.07.Q3 earnings per share view $0.02 -- Thomson Reuters I/B/E/S.  Full Article